Bristol-Myers acquires iPerian for $175M Bristol-Myers Squibb and iPierian announced Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies. The acquisition gives Bristol-Myers Squibb full rights to iPierianís asset IPN007, a preclinical monoclonal antibody that represents a new approach to treat progressive supranuclear palsy and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early FY15. Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierianís issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175M, with the potential for additional development and regulatory milestone payments totaling $550M, along with future royalties on net sales. The transaction is expected to be accounted for as an asset acquisition for Bristol-Myers Squibb resulting in a $175M charge during 2Q14.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.